Naohiko Nakamura

Toyama, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 52 publications

Suvorexant Prescription-Record Rates After a Palliative Care Pocket Manual Revision: A Single-Centre Interrupted Time Series Study.

Suvorexant Prescription-Record Rates After a Palliative Care Pocket Manual Revision: A Single-Centre Interrupted Time Series Study.

Journal: Journal of pain & palliative care pharmacotherapy

Published: August 19, 2026

Facility-Level Availability of Japanese Society of Medical Oncology Specialists and Recorded First-Line Treatment-Process Duration in Pancreatic Cancer: A Nationwide Center for Cancer Genomics and Advanced Therapeutics Registry Analysis.

Facility-Level Availability of Japanese Society of Medical Oncology Specialists and Recorded First-Line Treatment-Process Duration in Pancreatic Cancer: A Nationwide Center for Cancer Genomics and Advanced Therapeutics Registry Analysis.

Journal: Current oncology (Toronto, Ont.)

Published: May 09, 2026

Facility-level JSMO specialist availability and reconstructable treatment-process measures in colorectal cancer using C-CAT data.

Facility-level JSMO specialist availability and reconstructable treatment-process measures in colorectal cancer using C-CAT data.

Journal: International journal of clinical oncology

Published: May 08, 2026

Comprehensive Genomic Profiling Timeliness Beyond Laboratory Turnaround Time: A Patient-Facing Pathway Analysis.

Comprehensive Genomic Profiling Timeliness Beyond Laboratory Turnaround Time: A Patient-Facing Pathway Analysis.

Journal: Asia-Pacific journal of clinical oncology

Published: April 25, 2026

Implementation Benchmark of Tumor-Agnostic Eligibility Signals Across Routine Comprehensive Genomic Profiling Platforms in Japan: A Nationwide C-CAT Analysis.

Implementation Benchmark of Tumor-Agnostic Eligibility Signals Across Routine Comprehensive Genomic Profiling Platforms in Japan: A Nationwide C-CAT Analysis.

Journal: Current oncology (Toronto, Ont.)

Published: April 19, 2026

Observed ALK fusion/rearrangement frequency across comprehensive genomic profiling platforms in Japanese routine oncology practice.

Observed ALK fusion/rearrangement frequency across comprehensive genomic profiling platforms in Japanese routine oncology practice.

Journal: International journal of clinical oncology

Published: April 12, 2026

Relationship between metabolic syndrome-related parameters and endoscopic classification of gastroesophageal reflux disease: a Japanese health checkup cohort study.

Relationship between metabolic syndrome-related parameters and endoscopic classification of gastroesophageal reflux disease: a Japanese health checkup cohort study.

Journal: Esophagus : official journal of the Japan Esophageal Society

Published: April 02, 2026

High intrapancreatic fat deposition accelerates pancreatic ductal adenocarcinoma growth and metastasis with enrollment of FABP5 upregulation.

High intrapancreatic fat deposition accelerates pancreatic ductal adenocarcinoma growth and metastasis with enrollment of FABP5 upregulation.

Journal: Scientific reports

Published: October 18, 2025

Electronic Structure of the S1 State Manganese Cluster in Photosystem II Investigated Using Q‑Band Selective Hole-Burning.

Electronic Structure of the S1 State Manganese Cluster in Photosystem II Investigated Using Q‑Band Selective Hole-Burning.

Journal: ACS physical chemistry Au

Published: July 19, 2025

Inhibition of fatty acid binding protein suppresses pancreatic cancer progression and metastasis.

Inhibition of fatty acid binding protein suppresses pancreatic cancer progression and metastasis.

Journal: Scientific reports

Published: March 17, 2025

CDX2 Promoter-Controlled Oncolytic Adenovirus Suppresses Tumor Growth and Liver Metastasis of Colorectal Cancer.

CDX2 Promoter-Controlled Oncolytic Adenovirus Suppresses Tumor Growth and Liver Metastasis of Colorectal Cancer.

Journal: Cancer science

Published: December 11, 2024

Development of a novel oncolytic adenovirus controlled by CDX2 promoter for esophageal adenocarcinoma therapy.

Development of a novel oncolytic adenovirus controlled by CDX2 promoter for esophageal adenocarcinoma therapy.

Journal: Journal of gastroenterology

Published: April 01, 2024

Showing 1-12 of 52

Last Updated: 09/26/2026